PCR Journal Club

The FUTURE Trial is a prospective randomised, multicentre, open label superiority trial comparing an FFR guided treatment strategy to traditional angiography guided treatment strategy on clinical outcomes in an all-comer population with multivessel coronary artery disease.

There are limited data evaluating long-term outcomes of IVUS use in patients with acute myocardial infarction (AMI). The aim of this study was to examine the impact of IVUS-guided PCI on long-term clinical outcomes in patients with AMI.

To further investigate the treatment effects of ticagrelor monotherapy compared with ticagrelor plus aspirin in a contemporary HBR population, a pre-specified analysis of the TWILIGHT trial, TWILIGHT-HBR, was conducted by using the Academic Research Consortium (ARC) criteria for HBR.

The objective of the IAMI1 trial was to determine whether early influenza vaccination reduces the risk of cardiovascular events in patients admitted with an acute-MI or high-risk stable coronary artery disease in an adequately powered randomized control trial setting.

The IMICA trial explored the effect of a single 1-hour infusion of Tocilizumab, initiated in patients as early as feasible in their hospital admission, post-cardiac arrest, and sought to investigate whether this would reduce the systemic inflammatory response.

The aims of this study were to assess the use of antiplatelet drugs in medically treated spontaneous coronary artery dissection (SCAD) patients and to investigate the relationship between single (SAPT) and dual (DAPT) antiplatelet regimens and 1-year patient outcomes.

Find out more about the results of this analysis which suggest that operator experience may be an important effect modifier in ROTA-PCI.

The HOST-EXAM trial sought to define whether, after DAPT for PCI with DES, clopidogrel monotherapy is associated with improved outcomes compared with aspirin monotherapy.

Using patient-level data from the Disrupt CAD I, II, III and IV trials, this pooled analysis assesses the efficacy and safety of intravascular lithotripsy in de novo calcified coronary lesions.

The PIONEER III trial aims to assess the effectiveness and safety of the biodegradable-polymer sirolimus-eluting Supreme stent compared to durable-polymer everolimus-eluting stent (Xience or Promus), completely releasing the drug by 120 days.